RGEN: Record Q3 growth and stronger FY26 guidance, with BioLife adding a partial-quarter contribution

What happened

Q3 revenue reached $209M, up 12.5% organically, led by strength in Chromatography and Proteins. Adjusted EPS rose 15% to $0.53, and FY26 organic growth guidance was raised to 12%-13%, including a partial-quarter BioLife contribution.

Confirmed

Global impact / market context

Faster organic growth means more sales from existing operations rather than acquisitions. Higher adjusted EPS, which means profit per share excluding certain items, shows earnings rose alongside revenue. The raised FY26 guidance signals management expects the BioLife deal and core demand to lift future results.

Analyst inference

Investors compare organic growth with acquisition-driven growth because it shows underlying demand. A guidance raise including only a partial BioLife quarter implies the acquired business could add more in later periods, which may shape expectations for revenue and earnings beyond this year.

Analyst inference

What to watch

1. FY26 organic growth guidance was raised to 12%-13%, including only a partial-quarter BioLife contribution, so watch for updates on how much BioLife adds in future periods. Confirmed
2. Watch whether Chromatography and Proteins, the segments cited for Q3 strength, keep growing, since slower demand there would directly reduce revenue and pressure the raised guidance. Proposed
3. Track adjusted EPS, which means profit per share excluding certain items, because a 15% rise outpaced revenue growth, and any reversal in costs or deal expenses could change that relationship. Analyst inference

Evidence

• Original source link unavailable